CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer

Prior treatment

• Prior therapy: ADT, second-generation androgen receptor inhibitors, CYP17 enzyme inhibitors, any chemotherapy or immunotherapy for prostate cancer, radiotherapy (external radiation radiotherapy, brachytherapy, or radiopharmaceuticals);
• Known hypersensitivity to any of the investigational drugs, or excipients in the preparations;
• Any of the following conditions within 6 months prior to randomization: stroke, myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, or congestive heart failure (New York Heart Association cardiac function class III or IV);
• Prior (28 days prior to initiation of study drug or 5 half-lives of investigational therapy from a prior study, whichever is longer) or concurrent participation in another clinical study of study drug;
• Inability to swallow oral medications;

Other illness

• uncontrolled hypertension as evidenced by a resting systolic blood pressure ≥ 160 mm Hg or diastolic blood pressure ≥ 100 mm Hg after treatment
• History of prior malignancy, except basal cell or cutaneous squamous cell carcinoma in complete remission;
• History of gastrointestinal disorders or surgery expected to significantly interfere with the absorption of study drug(s);
• Active acute and chronic viral hepatitis, known HIV infection;
• Any other serious or unstable medical condition or condition that may interfere with their participation in the study or the evaluation of study results or may jeopardize the safety of the trial and other conditions;

Other

• Contraindication to CT/MRI examination;
• A close interest in the research center.

• Fully understand the purpose of this trial and sign a written informed consent;
• Men aged 18-85 years;
• have histologically or cytologically confirmed adenocarcinoma of the prostate;
• Have multiple metastatic disease, defined as follows: according to RECIST v1.1, metastatic disease was defined as metastatic foci detected on bone scans or measurable lymph nodes or soft tissue or visceral lesions above the aortic bifurcation. Lymph nodes were defined as measurable if their short-axis diameter was ≥15 mm; soft tissue/visceral lesions were defined as measurable if their long-axis diameter was ≥10 mm. and total number of metastatic lesions ≥ 5. Patients with only regional lymph node metastases (N1, below the aortic bifurcation) were not eligible for the study.
• At the investigator's discretion, patients must meet the indications for ADT and docetaxel;
• Patients have not received any prior local or systemic therapy for prostate cancer primary or metastasis.
• Eastern Cooperative Oncology Group (ECOG) score of 0-1;
• Blood count at screening: hemoglobin ≥ 9.0 g/dL, absolute neutrophil count ≥ 1.5 x 10\^9/L, and platelet count ≥ 100 x 10\^9/L (patient has not received any colony-stimulating factor within 4 weeks or a transfusion or blood product within 7 days prior to blood collection)
• Serum alanine aminotransferase and/or aspartate aminotransferase ≤ 1.5 x Upper limit of normal (ULN), total bilirubin ≤ ULN, creatinine ≤ 2.0 x ULN.